In Vitro Efficacy of Quinolones and Carbapenems against Nonfermenting Gram-Negative Bacteria Isolated from Clinical Specimens in a Nepalese Tertiary Care Hospital
Abstract
Nonfermenting Gram-negative bacteria (NFGNB) pose a significant public health threat due to multidrug resistance (MDR) mediated by biofilms, efflux pumps, and carbapenemases. This cross-sectional study evaluated the minimum inhibitory concentrations (MICs) of quinolones and carbapenems against the Acinetobacter calcoaceticus-baumannii (ACB) complex and Pseudomonas aeruginosa isolated from clinical specimens at the Nepal Armed Police Force Hospital, Balambu, Kathmandu, Nepal. These NFGNB were isolated and identified using standard microbiological methods. Quinolone- and carbapenem-resistant isolates, screened by disc diffusion, were tested for MICs of quinolones and carbapenems using broth microdilution. Statistical analyses were performed in SPSS v. 17.0. Ninety-two NFGNB were isolated, predominantly from urine (40.2%; 37/92). The MDR proportion was high in P. aeruginosa (85.7% [18/21] versus 80.28% [57/71]). The extensively drug-resistant (XDR) proportion was high in the ACB complex (14.1% [10/71] versus 4.8% [1/21]). The MIC50 in P. aeruginosa against norfloxacin and ofloxacin was ≥8 and ≥0.5 µg/mL, respectively. The MIC50 against ciprofloxacin in P. aeruginosa was ≥8 µg/mL, whereas it was ≥32 µg/mL in the ACB complex. MIC50 against levofloxacin was ≥0.5 µg/mL in P. aeruginosa, unlike the ACB complex (≥16 µg/mL). The MIC50 for meropenem was lower in the ACB complex (≥4 versus ≥8 µg/mL) than in P. aeruginosa, whereas both showed similar MIC90 (≥64 µg/mL). ACB complex showed…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.